Pipeline

Overview

Overview


We are developing a pipeline of purpose-built, targeted medicines against genetic drivers of cancer. By designing highly selective medicines, we have the potential to deliver treatments that increase clinical benefit in genetically defined patient populations and fulfill the promise of precision medicine for appropriate patients.

Program Indication


Larotrectinib (LOXO-101) Cancers Harboring Alterations of Tropomyasin Receptor Kinase (TRK)

Worldwide Commercial rights: Loxo Oncology, Inc.

Preclinical
Phase 1
Phase 2
Registration
Phase 2 Basket Trial
Status: Adult/adolescent solid tumors with TRK fusions, currently enrolling
NCI-MATCH Trial
Status: Phase 2 Multi-Sponsor Umbrella Protocol Across >900 Sites Nationwide larotrectinib (LOXO-101) for TRK Fusions
Adult Phase 1 Trial
Status: Continue to follow enrolled TRK fusion patients; explore non-fusion TRK biology, currently enrolling
Pediatric Phase 1/2 Trial
Status: Pediatric Solid or Primary CNS Tumors, Currently Enrolling

LOXO-195 (TRK inhibitor) Next-Generation TRK Inhibitor for Potential Acquired Resistance

Worldwide Commercial rights: Loxo Oncology, Inc.

Preclinical
Phase 1
Phase 2
Registration
Status: Initiate Phase 1 Trial in Mid-2017

LOXO-292 (RET inhibitor) Cancers Harboring Alterations of Rearranged During Transfection (RET)

Worldwide Commercial rights: Loxo Oncology, Inc.

Preclinical
Phase 1
Phase 2
Registration
Status: Initiate Phase 1 Trial in Early 2017

FGFR Program Cancers Harboring Alterations of Fibroblast Growth Factor Receptor (FGFR)

Worldwide Commercial rights: Loxo Oncology, Inc.

Preclinical
Phase 1
Phase 2
Registration
Status: Lead Optimization